References
- Topalian SL, Drake CG, Pardoll DM. Immune check- point blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–461.
- Pardoll DM. Immunology beats cancer: a blueprint for successful translation. Nat Immunol. 2012;13:1129–1132.
- Postow MA, Callahan MF, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33:1974–1982.
- Johnson DB, Peng C, Sosman JA. Nivolumab in melanoma: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7:97–106.
- Daud A, Ribas A, Robert C, et al. Long-term efficacy of pembrolizumab in a pooled analysis of 655 patients with advanced melanoma enrolled in KEYNOTE-001 [abstract]. J Clin Oncol (Meeting Abstracts). 2015;33:9005.
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–1117.
- Patnaik A, Kang SP, Rasco D, et al. Phase I study of pembrolizumab (MK-3475;anti–PD-1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res. 2015;21:4286–4293.
- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet. 2015;16:908–918.
- Puzanov I, Dummer R, Schachter J, et al. Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (MK-3475) versus chemotherapy in patients with ipilimumab- refractory advanced melanoma [abstract]. J Clin Oncol (Meeting Abstracts). 2015;33:3012.
- Daud A. Current and emerging perspectives on immunotherapy for melanoma. Semin Oncol. 2015;42(Suppl 3):S3–S11.
- Robert C, Schachter J, Long GV, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521–2532.
- Robert C, Min L, Joshua AM, et al. Immune-related thyroid disorders with pembrolizumab (MK-3475) in patients with advanced melanoma treated in KEYNOTE-001 [abstract]. J Clin Oncol (Meeting Abstracts). 2015;33:9050.
- Sanlorenzo M, Vujic DA, et al. Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015;151:1206–1212.
- Wolchok JD, Hoos A, O’Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412–7420.